Affordable Access

Prostacyclin Production Following In Vitro Mixing of Normal With Hemolytic-Uremic-Syndrome Serum

Authors
  • Richard L. Siegler
  • Jean B. Smith
  • Michael B. Lynch
  • Syed F. Mohammad
Publication Date
Jul 01, 1988
Source
PMC
Keywords
License
Unknown

Abstract

Serum from patients with the hemolytic-uremic syndrome (HUS) usually has a diminished ability to support the production of prostacyclin (prostaglandin [PG] I2). An impaired ability to produce this potent antiaggregatory substance could account for the thrombotic microangiopathy that is characteristic of the syndrome.

Report this publication

Statistics

Seen <100 times